Clinical Journal of the American Society of Nephrology最新文献

{"title":"Progress Toward a Better Predictor of Remission in Anti-Phospholipase A2 Receptor-Associated Membranous Nephropathy.","authors":"Patrick H Nachman","doi":"10.2215/cjn.0000000737","DOIUrl":"https://doi.org/10.2215/cjn.0000000737","url":null,"abstract":"","PeriodicalId":50681,"journal":{"name":"Clinical Journal of the American Society of Nephrology","volume":"53 1","pages":""},"PeriodicalIF":9.8,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Video-Assisted Electronic Consent versus Standard Consent for Percutaneous Kidney Biopsy.","authors":"Thelma Barber","doi":"10.2215/cjn.0000000736","DOIUrl":"https://doi.org/10.2215/cjn.0000000736","url":null,"abstract":"","PeriodicalId":50681,"journal":{"name":"Clinical Journal of the American Society of Nephrology","volume":"13 1","pages":""},"PeriodicalIF":9.8,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How I Approach Hematuria and Proteinuria: Can We Prevent the Same Mistake from Happening Twice?","authors":"Timothy T. Yau","doi":"10.2215/cjn.0000000752","DOIUrl":"https://doi.org/10.2215/cjn.0000000752","url":null,"abstract":"An abstract is unavailable. This article is available as a PDF only.","PeriodicalId":50681,"journal":{"name":"Clinical Journal of the American Society of Nephrology","volume":"14 1","pages":""},"PeriodicalIF":9.8,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144097584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Lowering Dietary Phosphorus Additive Intake on Mineral Metabolism in Adults with and without Chronic Kidney Disease.","authors":"Muhammad Bilal Khan,Mercedes R Carnethon,Tamara Isakova,Myles Wolf,Orlando M Gutiérrez","doi":"10.2215/cjn.0000000730","DOIUrl":"https://doi.org/10.2215/cjn.0000000730","url":null,"abstract":"BACKGROUNDExcess phosphorus additive intake leads to alterations in phosphorus metabolism that are linked to cardiovascular and kidney disease. The effects of lowering phosphorus additive intake in adults with and without chronic kidney disease (CKD) are unclear.METHODSWe conducted a feeding study in 39 adults without and 11 adults with CKD. Participants were fed a phosphorus additive-enhanced diet for two weeks followed by a low additive diet for six weeks. Both diets were identical except for phosphorus additive content. Blood and urine samples were collected at regular intervals with analyses comparing follow-up measures of mineral metabolism markers to baseline values.RESULTSThe mean (SD) age of the non-CKD group was 34(12) years, among whom 51% were male, 36% were of Black race, and mean (SD) eGFR was 106(16) ml/min/1.73m2. The mean (SD) age of the CKD group was 72(6) years, among whom 36% were male, 82% were of Black race, and mean (SD) eGFR was 35(13) ml/min/1.73m2. After consuming the additive-enhanced diet for two weeks, consuming the low additive diet for six weeks decreased 24-hour urine phosphorus excretion by ∼30% in both groups. In the non-CKD group, the effect of the low additive diet on circulating fibroblast growth factor 23 (FGF23) concentrations differed by race (Pinteraction=0.03)-FGF23 decreased by 22% from baseline in White adults (P<0.001) but not in Black adults (P=0.08). In the CKD group, FGF23 decreased 25% after six weeks of the low additive diet (P<0.001) with no difference by race. Intact parathyroid hormone (PTH) concentrations decreased 20% in CKD participants and did not change in the non-CKD participants.CONCLUSIONSix weeks of a low phosphorus additive diet decreased FGF23 and PTH in adults with moderate CKD. Lowering phosphorus additive intake lowered FGF23 in White adults without CKD but had no effect in Black adults without CKD.","PeriodicalId":50681,"journal":{"name":"Clinical Journal of the American Society of Nephrology","volume":"96 1","pages":""},"PeriodicalIF":9.8,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143945506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tangled Threads: Unravelling a Case from Kidney Allograft Loss to Re-Transplantation","authors":"Christie Rampersad, Ian W. Gibson, James Shaw, Julie Ho","doi":"10.2215/cjn.0000000748","DOIUrl":"https://doi.org/10.2215/cjn.0000000748","url":null,"abstract":"An abstract is unavailable. This article is available as a PDF only.","PeriodicalId":50681,"journal":{"name":"Clinical Journal of the American Society of Nephrology","volume":"25 1","pages":""},"PeriodicalIF":9.8,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143933566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Finerenone and Clinical Outcomes in Chronic Kidney Disease and Type 2 Diabetes by Frailty Index: FIDELITY Post Hoc Analysis.","authors":"Peter Rossing,Andreas L Birkenfeld,Paola Fioretto,Janet B McGill,Stefan D Anker,Bertram Pitt,Katja Rohwedder,Andrea Scalise,Charlie Scott,Gerasimos Filippatos,","doi":"10.2215/cjn.0000000700","DOIUrl":"https://doi.org/10.2215/cjn.0000000700","url":null,"abstract":"INTRODUCTIONFrailty is associated with a higher risk of adverse outcomes. It is believed that people with a higher frailty index may be less tolerant to new treatments, often leading to inappropriate prescribing. This post hoc analysis of FIDELITY, a prespecified, pooled analysis of the FIDELIO-DKD and FIGARO-DKD phase 3 clinical trials, investigated the efficacy and safety of finerenone versus placebo according to baseline frailty index.METHODSBetween September 2015 and October 2018, 12,990 people with chronic kidney disease (CKD) and type 2 diabetes (T2D) receiving the maximum tolerated dose of a renin-angiotensin system inhibitor were randomized to receive finerenone 10 or 20 mg once daily or placebo. Baseline frailty index was calculated using the Rockwood cumulative deficit approach including 30 clinical characteristics. Primary efficacy outcomes included a kidney (kidney failure, sustained decrease of ≥57% in estimated glomerular filtration rate [eGFR], or kidney-related death) and a cardiovascular (CV) composite outcome (CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure). Changes in urine albumin-to-creatinine ratio (UACR) and eGFR were measured across the study period.RESULTSOverall, kidney and CV event rates increased with increasing frailty. Finerenone reduced the risk of primary kidney and CV composite outcomes irrespective of baseline frailty (P interaction=0.93 and 0.35, respectively). Compared with placebo, finerenone also demonstrated significant reductions in UACR across all frailty subgroups (P<0.01 for all visits) and significant attenuation of eGFR decline from baseline to month 48 in the three most frail quartiles (>Q1 to ≤Q2, P=0.001; >Q2 to ≤Q3, P<0.001; >Q3, P<0.001, respectively). The incidence of serious adverse events and hyperkalemia increased with increasing frailty in both treatment arms.CONCLUSIONFinerenone reduced the risk of CV and kidney events in people with CKD and T2D versus placebo irrespective of baseline frailty status.REGISTRATIONFIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049).","PeriodicalId":50681,"journal":{"name":"Clinical Journal of the American Society of Nephrology","volume":"6 1","pages":""},"PeriodicalIF":9.8,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143903104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Noninvasive Diagnostic Strategies for Membranous Nephropathy in the Nephrotic Syndrome Study Network.","authors":"Jarcy Zee, Jonathan J Hogan, Ahmed Abdullah, Lili Liu, Krzysztof Kiryluk, Laurence H Beck","doi":"10.2215/CJN.0000000671","DOIUrl":"10.2215/CJN.0000000671","url":null,"abstract":"","PeriodicalId":50681,"journal":{"name":"Clinical Journal of the American Society of Nephrology","volume":" ","pages":"697-705"},"PeriodicalIF":8.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143527971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-Diversity Plant-Based Diets in CKD: Key Considerations from a Patient's Perspective.","authors":"Edson Arakaki","doi":"10.2215/CJN.0000000712","DOIUrl":"10.2215/CJN.0000000712","url":null,"abstract":"","PeriodicalId":50681,"journal":{"name":"Clinical Journal of the American Society of Nephrology","volume":" ","pages":"591"},"PeriodicalIF":8.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143804709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination Automated Microfluidics Measurement of Urine C-C Motif Ligand 2, CXC-Motif Chemokine 9, CXC-Motif Chemokine 10, and Vascular Endothelial Growth Factor A for Monitoring Patients with a Kidney Transplant.","authors":"Michael E Seifert, Alvin T Kho, Lea Sheward, Nancy Rodig, Sarah Goldberg, Margaret Diehl, David Zurakowski, Roslyn B Mannon, Vikas R Dharnidharka, Oriol Bestard, Tom D Blydt-Hansen, David M Briscoe","doi":"10.2215/CJN.0000000666","DOIUrl":"10.2215/CJN.0000000666","url":null,"abstract":"","PeriodicalId":50681,"journal":{"name":"Clinical Journal of the American Society of Nephrology","volume":" ","pages":"719-732"},"PeriodicalIF":8.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Metabolomic Markers of Dietary Potassium and Risk of CKD.","authors":"Lauren Bernard, Jiaqi Yang, Jingsha Chen, Valerie K Sullivan, Bing Yu, Eugene P Rhee, Paul A Welling, Casey M Rebholz","doi":"10.2215/CJN.0000000675","DOIUrl":"10.2215/CJN.0000000675","url":null,"abstract":"","PeriodicalId":50681,"journal":{"name":"Clinical Journal of the American Society of Nephrology","volume":" ","pages":"642-651"},"PeriodicalIF":8.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097188/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}